Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Key Takeaway: Alkermes plc has appointed Anne C. Whitaker as an independent director on its Board of Directors. Ms. Whitaker is recognized for her extensive experience in the biopharmaceutical sector, contributing valuable commercial and operational insights. Her appointment is seen as timely for the company's growth and transformation efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a seasoned executive to the Board.
  • Brings deep commercial and operational expertise.
  • Proven track record of driving growth in biopharma.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
2.8%
average across 7 past catalysts
Lead asset
ALKS 2680
Phase 2 · Idiopathic Hypersomnia

Full Press Release Details

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. “Anne joins our Board at a defining time for

Frequently Asked Questions

Who is the new director appointed to Alkermes' Board?

Anne C. Whitaker has been appointed as the new independent director.

What expertise does Anne C. Whitaker bring?

She brings deep commercial and operational expertise in biopharma.

Why is this appointment significant for Alkermes?

It comes at a defining time for the company's growth and transformation.

Last updated: Sep 16, 2026